---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005168"
form_type: "8-K/A"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-08-04T11:01:21+00:00"
generated_at: "2026-08-04T11:06:04.886743+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioCryst estimates $6.2-7.5M in severance costs for discovery program discontinuation

## Summary
- Plan to discontinue internal discovery programs and close Birmingham, AL facility announced June 29, 2026.
- One-time expenses of $6.2-7.5M for employee termination benefits and severance; $5.3-6.6M cash expenditures.
- Facility closure costs (contract/lease termination, asset impairment) not yet estimable; further filing expected.
- Restructuring part of strategic evolution to strengthen rare disease pipeline.

## SEC filing metadata
- accession: 0001171843-26-005168
- form_type: 8-K/A
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-08-04T11:01:21+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326005168/0001171843-26-005168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326005168/f8ka_080326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005168
- JSON: https://secwatch.observer/filing/0001171843-26-005168.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005168.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.